Reviving Polymyxins: Achievements, Lessons and the Road Ahead

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

2 Citations (Scopus)

Abstract

Antibiotic resistance has become the most significant threat to human health across the globe. Polymyxins are often used as the only available therapeutic option against Gram-negative ‘superbugs’, namely Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae. The limited pharmacological and clinical knowledge on the polymyxins in the old literature substantially limited optimizing their clinical use. The current chapter provides a general introduction to this first-ever polymyxin book which comprehensively reviews the significant progress over the last two decades in the chemistry, microbiology, pharmacology, clinical use and drug discovery of polymyxins. In particular, recent pharmacological results have led to the first scientifically-based dosing recommendations and facilitated the discovery of new-generation polymyxins. Future challenges in polymyxin research are highlighted, aiming at improving the clinical utility of this last-line defence.

Original languageEnglish
Title of host publicationPolymyxin Antibiotics
Subtitle of host publicationFrom Laboratory Bench to Bedside
EditorsJian Li, Roger L. Nation, Keith S. Kaye
Place of PublicationSwitzerland
PublisherSpringer
Chapter1
Number of pages8
Edition1st
ISBN (Electronic)9783030163730
ISBN (Print)9783030163716
DOIs
Publication statusPublished - 2019

Publication series

NameAdvances in Experimental Medicine and Biology
Volume1145
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019

Keywords

  • Antibiotic resistance
  • Clinical use
  • Drug discovery
  • Pharmacology
  • Polymyxin

Cite this